BioPharm International's BP Elements, August 2022

The clinical trial research environment has evolved because of specific solutions designed to overcome uncertainty.

Preclinical testing is better able to evaluate complex drug candidates thanks to innovations in animal model approaches.

La Jolla’s acquisition of Carterra’s LSA Platform is designed to advance their immunological and infectious disease research.

Synthego has launched new engineered cell libraries to validate targets for quicker drug discovery timelines.

Bio-Rad has expanded its range of recombinant monoclonal anti-idiotypic antibodies.

Shimadzu’s new ultra-high performance liquid chromatography system is designed to solve common problems in biopharma analysis.

Roche’s new test is the first available immunoassay that allows for simultaneous, independent determination of the hepatitis C virus antigen and antibody status.

Discovery Life Sciences’ acquisition of AllCells is intended to bolster its cell and gene therapy products and services.

The PerkinElmer Flow Cytometry Instrument Concierge Services will provide biopharmaceutical labs with expert, on-site flow cytometry specialists.

Merck, known as MSD outside the United States and Canada, now offers the Merck Digital Sciences Studio, designed to enable innovative tech for drug discovery and development.

Pfizer and Touchlight have signed a patent license agreement for Pfizer to use Touchlight’s doggybone DNA (dbDNA) in the manufacture of mRNA vaccines, therapeutics, and gene therapies.